The future of intelligent plant-based ingredients

Using our cutting-edge artificial intelligence technology platform, we unlock healthier, safer and smarter ingredients from nature.

Nature

We discover, unlock and clinically demonstrate the efficacy of the superpowers of nature hidden within peptides.

Consumer

To empower consumers to live healthier lives, naturally by making the products they consume everyday safer, healthier and greener.

Customer

To help our customers innovate at speed with unique and exclusive bioactive peptides.

Our Vision

At Nuritas, we make everyday products safer, healthier and greener!

Using our AI Magnifier technology platform and the transformative power of intelligent, patented peptides that are hidden in nature, we empower people everywhere to live naturally healthier lives.​

Our Team

The beating heart of Nuritas is our incredibly passionate team

At Nuritas, our passionate team features a mix of different nationalities. We are very proud of our gender balance with 50% women and men across our team.

OUR SCIENTIFIC ACHIEVEMENTS

0

860 years of cumulative research experience

860 years of cumulative research experience

0

15 peer reviewed papers published

15 peer reviewed papers published

0

59 patents issued or pending

59 patents issued or pending

OUR HISTORY

Through years of research...

Nuritas has learnt to speak the language of life and translate nature into innovation.

Timeline

Scroll to read more

Our People

Team

Dr Shweta Shah

Close

close

Dr Shweta Shah

Head of Regulatory Affairs

Shweta is an experienced regulatory professional with expertise in nutraceuticals, dietary supplements, proteins, and excipients. She brings over 20 years of experience in R&D and business development through regulatory and scientific guidance. She holds an M.Tech. and Ph.D. in Enzymology from the Indian Institute of Technology Delhi, India. Before joining Nuritas, she worked as Regulatory and Scientific Affairs Manager in Kemin Human Nutrition and Health. She led the registration of novel food/dietary ingredients globally and provided regulatory/scientific guidance for developing and substantiating claims for dietary/cosmetic ingredients. Before this, she worked as a staff scientist at Iowa State University, where she coordinated and conducted research activities in protein biochemistry and related fields focused on structural and functional characterization of signal transduction proteins, development of novel concepts for studying protein-protein and protein-small molecule interactions.

Rizwan Khan

Close

close

Rizwan Khan

Head of Commercial - USA & Emerging Markets

Rizwan has decades of experience in leading commercial operations. He has primarily worked in the pharmaceutical, biotechnology, and nutraceutical areas for more than 35 years. His last role was at the Kerry Group for the last 14 years leading the commercial operations for the Kerry Pharma business globally.
Prior to Kerry Group, he was also previously at Novozymes, Sanofi, GSK and BMS.
Rizwan has also served in the USMC and USAF military branches as an officer, pilot and veteran. His undergraduate degree is in Finance and all his advanced studies have been completed in the USMC Officer’s School, USAF Aviation School, and at the IESE Executive Management school in Spain.

Close

close

Marie Bruckert

Head of Global Marketing

Marie has 20 years experience in BtoB and DtoC in all retail channels. Her contribution in the strategy, global marketing and communication of international brands like Yes Rocher and Nuxe and her Sales and business development experience have built a strong intrapreneur profile, driving the complete lifecycle of a brand.

Close

close

Dr Brian Keogh

Head of Biology

Brian is an immunologist with almost 20 years’ experience in the biotechnology and pharmaceutical industries. Having gained his Ph.D. from UCD under the supervision of Professors Brian Sheahan and Kingston Mills, he joined Opsona Therapeutics in 2004, where he occupied several roles. Most recently, he was the Head of In Vivo Pharmacology, leading the scientific development of a humanised monoclonal antibody against TLR2 from early-stage development to Phase II clinical trials in renal transplantation and myelodysplastic syndrome. He moved to Nuritas in 2019 where he and his team are responsible for the scientific development of a range of products from early-stage assay setup and screening to generation of clinical data for both internal pipeline and customer projects. He has over 25 publications and holds 4 patents.

Close

close

Sean McGrath

Chief HR Officer

Sean McGrath is a highly seasoned global CHRO and Executive VP, with extraordinary execution skills and a career in global, growing organizations in the USA and Ireland.
Sean holds a BA from University College Galway, a master’s from Dublin City University, and a doctorate in Business Administration from Durham University in the UK. After starting his career in the Irish Defense Forces, he then went on to lead a range of senior HR positions in both manufacturing and financial services organizations, before moving back to Ireland and joining the Health Service Executive (HSE) as their HR in 2007. Over the next five years, he led an HR Function for the largest workforce in Ireland where he oversaw 10 different public sector trade unions, representing over 110,00 staff across the country.
Following his time at the HSE he spent six years as the Executive Vice President at the World Bank Group in Washington DC. In this position he led a significant change program that ensured the Bank was positioned for its next phase of growth. Prior to his appointment at Nuritas, McGrath acted as the Chief People Officer for ContourGlobal PLC, a power generation business listed on the London Stock Exchange.

Close

close

Dr Henri Molhuizen

Chief Science Officer

Henri is a highly experienced R&D leader with a strong scientific background in the field of molecular cell biology. With over 22 years in business at large multi-nationals, he brings proven expertise in new development and innovation of Food & Beverage in various categories and across multiple geographies. His most recent role was Vice President of R&D at Dawn Foods where he owned all things innovation and led the European and AMEAP teams to deliver through each step of the R&D process.

Close

close

JC Bacos

Head of Commercial - EU

JC brings expertise from across a wide range of commercial areas, such as marketing, sales, supply and strategy with global experience across different continents and multiple channels, both from a B2B and B2C model. He was previously the Asia-Pacific Head for Bayer Consumer Health, based in Singapore. Prior to that, he was Laboratoire UPSA`s managing director in France. He has also held a variety of senior roles at Coca-Cola Austria and L’Oréal, from global marketing to leading regional and national operations. His wealth of experience in strategy, vision for the future and route to market will help lead the Nuritas team on a journey to transform human health by unlocking the power of nature.

Close

close

Neil Foster, MBA

Head of Strategic Partnerships (Consumer)

Neil has 20 years’ experience across a wide range of commercial functions in the food, nutrition and consumer health industries. He has been responsible for a number of global first-to-market launches, including novel health-promoting ingredients via some of the world’s largest food manufacturers and consumer health CPGs; but also branded D2C products both through eCommerce and traditional bricks-and-mortar retail.

Combining a degree in Nutritional Science with a business education from world renowned Henley Business School, Neil’s fascination is the intersection of technology, food and genomics and how these will converge to disrupt the traditional (and failing) healthcare model.

Marlene Connoly

Close

close

Marlene Connolly

Chief Legal Officer

Marlene has recently been appointed as Chief Legal Counsel for Nuritas, which combines artificial intelligence and genomics to discover and unlock natural bioactive peptides with extraordinary health benefits.

As former Group Counsel for Forcepoint International Technology Ltd. (a global cyber security company) Marlene has 25+ years’ in-house commercial experience in the Technology, Media, and Telecom Sector.

In 2007, Marlene set up Forcepoint’s International legal team (Dublin, Ireland) to support the Company’s business operations in EMEA and APAC. Over the past 14 years, Marlene grew the team to deliver EMEA & APAC legal support for strategic projects including Cybersecurity and Insider Threat roll out, GDPR readiness, together with Very Large Enterprise (VLE) sales agreements & professional services, HR matters, international expansion & governance, facilities, budgeting, litigation, and M&A & integration projects.

Prior to Forcepoint, Marlene was General Counsel and Company Secretary of Meteor Mobile. Before Meteor, Marlene led the legal team through M&A & integration projects for eir (formerly eircom) the principal provider of fixed-line and mobile telecommunications services in Ireland for 9 years.

In 2019, Marlene was elected to the board of Association of Corporate Counsel Europe, a pro bono position to support in-house counsel.

Legal500 selected Marlene for inclusion in the General Counsel Powerlist for Ireland in 2015 & 2017 and in 2016 Marlene’s team was selected by Legal 500 as GC Power list Ireland Teams.

Marlene is a graduate of ICSA (Institute of Chartered Secretaries and Administrators), a CEDR Accredited Mediator, achieved a Practitioner Certificate in Data Protection (PDP) in 2015, and achieved her Diploma in becoming a Chartered Director from IOD (Institute of Directors) in 2021.

In 2014 Marlene founded and previously chaired the GC forum within the Irish American Chamber of Commerce, providing an independent, peer-led safe space for an open exchange of ideas and challenges by US multinational GCs in Ireland.

Close

close

Owen Quinn

Chief Financial Officer

A fellow of the Chartered Association of Certified Accountants, Owen has 20+ years experience in FMCG with extensive fundraising and M&A experience.

Owen joined Nuritas in 2020, having spent the previous 5 years as CFO of a Global eCommerce and AI Technology start-up. Prior to that, he was CFO of an international FMCG business with customers such as Tesco, M&S, Aldi and Lidl. He also served time as the Finance Director of an IT multinational services company with major global customers such as Dell, Intel and Apple.

Owen has an MBA from Dublin City University and also completed the Stanford Graduate School of Business Strategic Leadership for CFO’s programme.

Owen has negotiated Long Term Agreements with some of the largest Technology and Retail Companies in the world and has extensive M&A and fundraising experience to fund global growth.

Close

close

Dr Nora Khaldi

FOUNDER AND CEO

Nora is a mathematician with a Ph.D. in Molecular Evolution and Bioinformatics. Nora’s research has focused primarily on protein evolution and comparative genomics.

Some of Nora’s publications have been placed in a library of the top 2% of published articles in the fields of biology and medicine.

Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms.

Previous to Nuritas™, Nora was the first scientist to show gene transfer between multi-cellular species. This ground-breaking find put into question many of the phylogenetic methods currently in use today.

Nora has developed a multitude of innovative software throughout her research career that are used to this day by research institutes and companies in over 70 countries. Nora has led international research teams around the world, in both academic and industrial settings, and has a proven record in new health-benefiting molecule discovery and commercialisation.

Over the next few years, Nora plans to lead the Nuritas™ team in their goal of reaching billions of people with their life-changing ingredients.

Board

Close

close

Randall Lewis

Randall has assisted companies in accessing capital as founder of Exodus Commercial Capital and has served as its President since 2013. He has over 30 years of finance and operations experience that includes Fortune 50 companies such as GE Capital, Wells Fargo and Anthem. Randall has held various executive leadership roles, including: Executive Vice President and Chief Compliance Officer, Executive Vice President and Chief Auditor and Managing Director of Corporate Development. His experience includes the closing of several mergers and acquisitions for over $2B. He also served as CEO for a start-up logistics firm, s2f worldwide, LLC; that was sold to a Fortune 500 company.

He obtained his Bachelor of Science degree in General Management/Accounting and MBA in Finance from Purdue University.

Close

close

Stephan Dolezalek

Stephan joined the Grosvenor Food & AgTech (formerly known as Wheatsheaf Group) Board as a Non-Executive Director in May 2017. Since then, he has assumed increasing responsibilities within the Group, becoming a full time Executive Director in January 2019.

Stephan has worked with entrepreneurial growth companies since the 1980s. He has been a private equity investor since 1999, investing in software, communications technology, biotechnology, clean energy and agricultural businesses. He led VantagePoint Capital Partners’ $1Bn CleanTech Fund from its inception. More recently he served as a senior advisor in forming the Breakthrough Energy Ventures fund and was the Managing Partner of Resourcient Group LLC. Stephan has also acted as co-founder of several companies and has helped “raise” five “unicorn” companies reaching valuations of between $1 and $100bn.
Stephan is a graduate of the School of Architecture at the University of Virginia (BCP) and the University of Virginia School of Law (JD).

Close

close

Nick Rosa

Nick Rosa is co-founder and Managing Director of Sandbox Industries and Managing Director of Cultivian Sandbox. Nick serves as a Director or advisor to several companies, such as the Blue Cross Blue Shield Venture Fund, Healthbox Global Partners, Oncology Analytics, Nuritas, TechStars Chicago and The Chicago Innovation Awards.

Prior to forming Sandbox, Nick led the buyout and served as CEO of The NutraSweet Company. As a senior executive at Monsanto, he led the Nutrition and Consumer Products division, overseeing NutraSweet, the consumer Lawn and Garden Business, and Kelco food ingredients business. Nick also served as a Senior Vice President and Advisor to the Board of Directors at Monsanto.

Previously, Nick held senior executive positions at Searle and has experience with Masonite Corporation and Baxter. He has lived and worked in several countries, including Kuwait, Switzerland and France. Nick has also been involved with numerous civic and commercial organizations. Nick holds a B.S. in Political Science from Northern Illinois University and an MBA from DePaul University.

Close

close

Mathieu Vermesch

Matthieu has over 25 years of experience in investment management with a focus on Asian regions. Matthieu’s investment experience has been centred primarily on thematic investing where he has successfully identified specific themes and designed strategies to profit from them. In mid-2012, Matthieu started to explore the imbalance created by China in the world market of animal protein. He quickly became convinced that it was the tipping point of a multi-decade investment opportunity. In late 2013-early 2014, Matthieu decided to concentrate solely on this and founded New Protein Capital (NPC). The scope of investment of NPC has since been expanded to include the multiple challenges of the food and feed production processes.

Prior to founding NPC in 2014, Matthieu was with Everest Capital, a large independent investment firm with offices in the US and in Singapore, for over 16 years. At Everest Capital, he was a Senior Managing Director and the Director of Research as well as a member of the Executive and Investment committees. Prior to Everest, Matthieu was with Banque Paribas, in Hong Kong, New York, Taipei and Paris.

Matthieu has a postgraduate degree in Corporate Finance from Université Paris Dauphine and has a graduate degree from Institut d’Etudes Politiques de Paris (Sciences Po).

Close

close

Dr Guru Ramanathan

Dr. Guru Ramanathan is a globally recognized expert in healthcare innovation and commercialization. He brings a wealth of experience from the clinical, consumer health, animal health and retail sectors. His most recent appointment was as Chief Innovation Officer for GNC, where he spent 15 years leading the development and launch of all products.

He previously held senior executive positions at Nutricia (Danone) and Scotia Pharmaceuticals. Guru is very active in nutrition industry initiatives and specialises in Clinical Trials Management, Consumer Health Product Development, DSHEA Regulatory Compliance, Management of Technology in Healthcare and Change Management.

Close

close

Dr Nora Khaldi

FOUNDER AND CEO

Nora is a mathematician with a Ph.D. in Molecular Evolution and Bioinformatics. Nora’s research has focused primarily on protein evolution and comparative genomics.

Some of Nora’s publications have been placed in a library of the top 2% of published articles in the fields of biology and medicine.

Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms.

Previous to Nuritas™, Nora was the first scientist to show gene transfer between multi-cellular species. This ground-breaking find put into question many of the phylogenetic methods currently in use today.

Nora has developed a multitude of innovative software throughout her research career that are used to this day by research institutes and companies in over 70 countries. Nora has led international research teams around the world, in both academic and industrial settings, and has a proven record in new health-benefiting molecule discovery and commercialisation.

Over the next few years, Nora plans to lead the Nuritas™ team in their goal of reaching billions of people with their life-changing ingredients.

Advisory board

Close

close

Joerg Ohle

Joerg is a career veteran of the consumer and animal health arena having spent over 40 years at Bayer. During his tenure with Consumer Health he held positions as commercial head where he oversaw all sales and marketing activities in the EU, Asia-Pacific, as well as Latin America, and was responsible for over €3 billion in annual revenues as well as the acquisition of a plant-based OTC company. Joerg was an executive board member of the consumer health division and lead the go-to-market council on worldwide activities.

Close

close

Dr Will Li

William W. Li, MD, is a world-renowned physician, scientist, speaker, and author of ‘Eat To Beat Disease – The New Science of How Your Body Can Heal Itself’. He is best known for leading the Angiogenesis Foundation. His ground-breaking work has impacted more than 70 diseases including cancer, diabetes, blindness, heart disease, and obesity. His TED Talk, “Can We Eat to Starve Cancer?” has garnered more than 11 million views, and he has appeared on: Good Morning America, CNN, MSNBC, NPR, Voice of America; and in The Atlantic, TIME, and The New York Times. An author of over 100 scientific publications in leading journals such as Science, the New England Journal of Medicine, and The Lancet, Dr. Li has served on the faculties of Harvard Medical School, Tufts University, and Dartmouth Medical School.

Close

close

Indra Nooyi

Currently a Board Member at Amazon, Mrs. Nooyi was the former Chief Executive Officer of PepsiCo, Inc., from October 2006 to October 2018, where she also served as the Chairman of its board of directors from May 2007 to February 2019. Having joined PepsiCo. in 1994, she held numerous positions including Chief Financial Officer as well as roles in corporate strategy and development and strategic planning. She has been regularly listed among the World’s 100 most influential women.

Close

close

Prof J Bruce German

Throughout his illustrious, 40-year research career, Prof. German’s pivotal research has focused on improving foods and their ability to positively impact on health, using milk as the genetic blueprint for how foods can support health. During his career, he has been named to the Most Highly Cited Scientists List by ISI Index and has received honours including the President’s Award Canadian Federation of Biological Societies, John E Kinsella endowed chair University of California and Mention D’Honneur Du Jury ACADEMI MORIM.

Close

close

Prof Justin Siegel

Prof. Siegel is a leading expert in methods that can rapidly and reliably discover novel enzyme catalysts, which has led to the discovery of enzymes with momentous functions including treating celiac disease and fighting anthrax infections. By leveraging breakthroughs from the field of synthetic biology, Prof. Seigel’s research team are capable of experimentally evaluating the properties of in silico designed proteins. His awards and honours include National Academies Education Fellowship, Alfred P. Sloan Research Fellowship and has served as the acting Director Innovation Institute for Food and Health, UC Davis.

 

Our investors

Ali Partovi

Bono

Edge

Marc Benioff